Press Release

November 1, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Exchange Plaza, Floor 25, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Kala Ghoda, Fort Mumbai – 400 051 Mumbai 400 001 Company Symbol: NEOGEN Scrip Code No: 542665 Debt Segment Code: 977028 Sub.: Press Release on the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, With reference to the captioned subject, please find enclosed herewith the Press Release on the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2026. The Press Release is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/ . Kindly take the same on your record. Thanking you, For Neogen Chemicals Limited Unnati Kanani Company Secretary and Compliance Officer Mem. No. A35131 Encl.: As above Registered Office: 1002, Dev Corpora, Cadbury Junction, E: investor@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 Q2 FY27 PRESS RELEASE Nov 1, 2026 Neogen Chemicals reports robust financial performance • Revenue at INR 296 crore, higher by 42% Y-o-Y • EBITDA at INR 45 crore, an increase of 51% Y-o-Y Neogen Chemicals Limited (Neogen) reported strong financial performance for the second quarter and half-year ended 30th September, 2026. In Q2 FY27 (consolidated), revenues stood at INR 296 crore, higher by 42% Y-o-Y. The Company delivered robust growth, despite challenges arising from geopolitical tensions in the Middle East, supply chain disruptions, and rising feedstock costs, driven by sustained volume growth across its core segments and anchored by Organolithium expansion into high-growth emerging applications. This was bolstered by accelerated scale up in Neogen Ionics (NIL) with Q2 FY27 revenue reaching INR 37 crore (vs. INR 5.4 crore in Q2 FY26). EBITDA for Q2 FY27 (consolidated) stood at INR 45 crore, higher by 51% Y-o-Y. Achieved strong EBITDA performance despite higher cost base related to Dahej plant rebuild, tolling arrangements, NIL capital expenditure, and elevated input costs. Consolidated EBITDA reflects the initial fixed-cost absorption at NIL, while revenue scale-up and capacity utilization are still ramping up, setting the foundation for future operating leverage. Neogen’s profit after tax for Q2 FY27 (consolidated) stood at INR 8 crore, higher by 144% Y-o-Y. PAT reflected core operational performance, impacted temporarily by higher interest and depreciation costs from ongoing CAPEX initiatives. Interest expenses are expected to decline moving ahead, supported by term debt reduction using QIP proceeds and lower borrowing costs following credit rating upgrade. Consolidated Earnings Per Share (EPS) for Q2 FY27 stood at INR 2.96 per share (not annualized). Performance at a Glance INR crore (Consolidated) Q2 FY27 YoY Growth Revenues 296* 42% Gross Profit 133 36% EBITDA 45 51% PAT 8 144% Note: Growth for Q2 FY27 is compared to Q2 FY26. * Consolidated Revenues include INR 37 crore from Battery Chemicals Page | 1 Press Release Commenting on the Q2 FY27 performance, Dr. Harin Kanani, Managing Director, Neogen Chemicals said: “We have delivered a robust all-round performance, demonstrating remarkable agility despite a challenging macroeconomic backdrop marked by geopolitical conflicts, supply chain friction, feedstock cost inflation, and the temporary unavailability of our Dahej facility. This performance underscores the resilience of our business model, as we swiftly pivoted toward applications with better demand visibility and higher volumes. This momentum was further reinforced by accelerated ramp-up in our Battery Chemicals business. In our Battery Chemicals business, we are transitioning from capital investment to execution and ramp-up phase. We continue to deepen our engagement with leading domestic and global cell manufacturers for supply of electrolyte and lithium salts. With upcoming ACC battery manufacturing plants coming online in India and a progressive shift by US electrolyte manufacturers toward sourcing from non-FEOC suppliers from India, we expect a substantial scale-up in Q4 FY27 and beyond. Our dual facilities at Dahej SEZ and Pakhajan are uniquely positioned to cater to these accelerated requirements, establishing Neogen as one of the largest Indian battery component manufacturers. A key strategic milestone during the period was the successful completion of our maiden QIP, raising INR 600 crore, which was oversubscribed 6.5x, drawing strong participation from marquee domestic and global institutional investors. This overwhelming response serves as a strong endorsement of market confidence in our long-term growth story. The proceeds are being strategically deployed toward de-leveraging our balance sheet, preparing for funding incremental business requirements and growth initiatives. Regarding our Dahej facility insurance claims, we are pleased to share that the majority of the recognized claim amount has already been received through successive on-account payouts. Discussions with the insurers for the remaining balance are progressing constructively, and we expect further settlements in due course as the final assessments conclude. Looking ahead, the outlook for both Neogen Standalone and our Battery Chemicals business remains encouraging as we enter the next phase of transformational growth, supporting India’s vision for self-reliance in the energy storage and advanced battery materials ecosystem. Guided by a clear execution roadmap and supported by a strengthened balance sheet, our full-year consolidated guidance remains on track as we stay focused on driving sustainable growth and delivering long-term value for our stakeholders.” Key Updates – Q2 FY27 (Neogen Chemicals) • Expansion of Organolithium manufacturing facility o The board has approved expansion of Organolithium facility at Patancheru, Telangana from 300 MTPA to 600 MTPA with proposed estimated investment of upto INR 45 crore with additional revenue potential of INR 150 to INR 200 crore based on lithium prices • Update on Dahej Fire Incident o Cumulative recoveries stand at INR 164 crore to date, comprising INR 155 crore in on- account insurance claims (including a recent tranche of INR 15 crore in July 2026) and INR Page | 2 Press Release 9 crore from salvage realization. Also incurred further incidental charges of INR 1 crore which is claimed as per insurance policy o On Oct 29, 2026, the Company accepted an additional claim amount of Rs. 152 crore from the insurance company, to be released in due course as part-payment of the total receivable o Total on-account claim received/ receivable stands at Rs. 316 crore, inclusive of above accepted claim and salvage scrap sales to date • Fund Raise o Raised INR 600 crore via first-ever QIP; Issue Oversubscribed by 6.5x o QIP attracted strong participation from a diverse mix of renowned domestic and global institutional investors o Proceeds utilized towards debt repayment, fund incremental business requirements and growth opportunities • Credit Rating o CRISIL Ratings revised the rating outlook on Neogen Chemicals Limited’s long-term bank facilities (INR 680 crore) and Non-Convertible Debentures (INR 200 Cr) to 'CRISIL A-/Stable' from 'Negative', while reaffirming short-term ratings at 'CRISIL A2+' UPDATE ON EXPANSION INITIATIVES Details of expansion projects announced: Current project updates: Battery Chemicals Business • 200 MTPA commissioned; first approval material shipped to the customers Capacity of 1,500 MTPA for manufacturing Lithium • Another 1,000 MTPA commissioned in Q2 FY27; Electrolyte Salts and Additives for rem [Showing first 8,000 characters — download PDF for full document]